健康受试者与脑肿瘤患者动态对比增强MRI血浆容积参数的可重复性
研究评估动态对比增强MRI提取的血浆容积(vp)在健康受试者中的可重复性,并定义纵向显著变化的阈值,同时评估高级别胶质瘤患者的变化。基于最小可检测差异(LDD)和推土机距离(EMD)的阈值分别为0.0024 ml/100 ml(21%)和4.14。初步结果提示vp-DCE参数可用于改善高级别胶质瘤患者的治疗反应评估。
要点
- 平均vp的LDD阈值为0.0024 ml/100 ml(21%),EMD阈值为4.14。
- 20/24次比较中正常表现脑组织vp无显著纵向变化。
- 约50%部分缓解病例出现vp显著升高而病灶体积显著缩小,2例先于进展。
核心结论
- 本研究显示vp具有高可重复性,并为脑肿瘤患者纵向评估的显著变化提供了阈值。
- 初步结果提示使用vp-DCE参数可改善高级别胶质瘤患者的治疗反应评估。
研究设计与样本
- 研究纳入28名健康受试者(其中11名扫描两次),用于评估正常表现脑组织中vp的可重复性,并基于平均vp的最小可检测差异(LDD)和直方图比较的推土机距离(EMD)定义显著变化阈值。
- 16例高级别胶质瘤患者接受纵向扫描,其中8例在贝伐珠单抗治疗前后扫描;基于定义的阈值评估纵向变化,并与RANO标准比较。
主要发现
- 显著变化阈值为:平均vp的LDD=0.0024 ml/100 ml(21%),EMD=4.14。
- 在患者中,20/24次比较未检测到正常表现脑组织内vp的显著纵向变化。
- 在诊断为进展性疾病的病例中,病灶体积变化(RANO标准)与LDD或EMD值结果一致;但在约50%诊断为部分缓解的病例中,尽管病灶体积显著缩小,初步结果显示vp显著升高。
- 在2例患者中,这些变化先于随访扫描检测到的进展。
- 总体而言,LDD与EMD之间获得良好一致性。
关键数值与推荐
- 平均vp的LDD阈值为0.0024 ml/100 ml(21%),EMD阈值为4.14。
- 正常表现脑组织中,20/24次比较未检测到vp的显著纵向变化。
- 约50%部分缓解病例中,病灶体积显著缩小而vp显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the repeatability of plasma volume (vp) extracted from dynamic-contrast-enhanced (DCE) MRI in order to define threshold values for significant longitudinal changes, and to assess changes in patients with high-grade-glioma (HGG). METHODS: Twenty eight healthy subjects, of which eleven scanned twice, were used to assess the repeatability of vp within the normal-appearing brain tissue and to define threshold values for significant changes based on least-detected-differences (LDD) of mean vp values and histogram comparisons using earth-mover's-distance (EMD). Sixteen patients with HGG were scanned longitudinally with eight patients scanned before and following bevacizumab therapy. Longitudinal changes were assessed based on defined threshold values in comparison to RANO criteria. RESULTS: The threshold values for significant changes were: LDD = 0.0024 (ml/100 ml, 21%) for mean vp and EMD = 4.14. In patients, in 20/24 comparisons, no significant longitudinal changes were detected for vp within the normal-appearing brain tissue. Concurring results were obtained between changes in lesion volume (RANO criteria) and LDD or EMD values in cases diagnosed with progressive-disease, yet in about 50% of cases diagnosed with partial-response preliminary results demonstrated significant increase in vp despite significant reductions in lesion volume. In two patients, these changes preceded progression detected at follow-up scans. In general, a good concordance was obtained between LDD and EMD. CONCLUSION: This study shows high repeatability of vp and provides threshold values for significant changes in longitudinal assessment of patients with brain tumors. Preliminary results suggest the use of vp-DCE parameter to improve assessment of therapy response in patients with high-grade-glioma.
引用
- Artzi M, Liberman G, Blumenthal DT, et al. Repeatability of dynamic contrast enhanced vp parameter in healthy subjects and patients with brain tumors. J Neurooncol. 2018. PMID: 30392091. doi:10.1007/s11060-018-03006-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。